![Rationale for eliminating the hormone‐free interval in modern oral contraceptives - London - 2016 - International Journal of Gynecology & Obstetrics - Wiley Online Library Rationale for eliminating the hormone‐free interval in modern oral contraceptives - London - 2016 - International Journal of Gynecology & Obstetrics - Wiley Online Library](https://obgyn.onlinelibrary.wiley.com/cms/asset/ab0b1b49-5065-4936-8b75-ce3294fa8113/ijgo8-fig-0001-m.jpg)
Rationale for eliminating the hormone‐free interval in modern oral contraceptives - London - 2016 - International Journal of Gynecology & Obstetrics - Wiley Online Library
Full article: Treatment continuation and satisfaction in women using combined oral contraception with nomegestrol acetate and oestradiol: a multicentre, prospective cohort study (BOLERO)
![Rupture de stock de Zoely : quelles alternatives ? - 28/11/2017 - Actu - Le Moniteur des pharmacies.fr Rupture de stock de Zoely : quelles alternatives ? - 28/11/2017 - Actu - Le Moniteur des pharmacies.fr](https://www.lemoniteurdespharmacies.fr/images/4e9/bd9d7761e5cadeeb30db8adc766ca.jpg)
Rupture de stock de Zoely : quelles alternatives ? - 28/11/2017 - Actu - Le Moniteur des pharmacies.fr
![Teva completes $703M sale of women's health products to CVC Capital Partners. - Philadelphia Business Journal Teva completes $703M sale of women's health products to CVC Capital Partners. - Philadelphia Business Journal](https://media.bizj.us/view/img/2625011/doctor-patient-consult*1024xx2121-1193-0-111.jpg)
Teva completes $703M sale of women's health products to CVC Capital Partners. - Philadelphia Business Journal
![HOOFDSITE Apotheker 3990 Peer : Substances actives - N - Nomégestrol (+ Estradiol) - ZOELY 3X28 COMP HOOFDSITE Apotheker 3990 Peer : Substances actives - N - Nomégestrol (+ Estradiol) - ZOELY 3X28 COMP](http://hoofd.mypharma.be/UserFiles/Uploads/images/Products/1000167/2836559.jpg)